⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5254652 | 1.00 | — | — | |
| SCHEMBL23336211 | 0.85 | — | — | |
| SCHEMBL11569345 | 0.81 | MAPT (0.67) | — | |
| SCHEMBL11412696 | 0.81 | MAPT (0.67) | — | |
| SCHEMBL27705009 | 0.78 | — | — | |
| SCHEMBL27685993 | 0.78 | — | — | |
| SCHEMBL1031070 | 0.78 | — | — | |
| SCHEMBL25364160 | 0.77 | — | — | |
| Potassium Ion SCHEMBL25367311 | 0.77 | — | — | |
| SCHEMBL2280835 | 0.77 | MAPT (0.36) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 57 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2408450-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | Bristol-Myers Squibb Company (US) | 2012-01-25 | — | — | EP | claimed |
| WO-2010107435-A1 | A NOVEL ALPHA-(N-SULFONAMIDO)ACETAMIDE COMPOUND AS AN INHIBITOR OF BETA AMYLOID PEPTIDE PRODUCTION | BRISTOL-MYERS SQUIBB COMPANY (US) | 2010-09-23 | — | — | WO | claimed |
| WO-1998027051-A9 | CATALYTIC ASYMMETRIC AMIDOHYDROXYLATION OF OLEFINS WITH N-HALO CARBOXAMIDES | — | 1998-11-12 | — | — | WO | claimed |
| WO-1998027051-A2 | CATALYTIC ASYMMETRIC AMIDOHYDROXYLATION OF OLEFINS WITH N-HALO CARBOXAMIDES | THE SCRIPPS RESEARCH INSTITUTE (US) | 1998-06-25 | — | — | WO | claimed |
| WO-2025262036-A1 | METHOD OF MANUFACTURING A PHARMACEUTICAL COMPOSITION | RNASSIST LTD (GB) | 2025-12-26 | — | — | WO | disclosed |
| EP-3827241-B1 | DISSOCIATION OF BIOLOGICAL SAMPLES | GOLDSBOROUGH ANDREW SIMON (FR) | 2024-03-13 | — | — | EP | disclosed |
| US-20240027309-A1 | SIMPLE FIXATION AND STABILISATION | RNASSIST LTD (GB) | 2024-01-25 | — | — | US | disclosed |
| US-20230220313-A1 | COMPOSITION AND METHOD FOR INACTIVATING A VIRUS | RNASSIST LTD. (GB) | 2023-07-13 | — | — | US | disclosed |
| EP-4133062-A1 | COMPOSITION AND METHOD FOR INACTIVATING A VIRUS | Rnassist Limited (GB) | 2023-02-15 | — | — | EP | disclosed |
| US-20210231538-A1 | DISSOCIATION OF BIOLOGICAL SAMPLES | GOLDSBOROUGH ANDREW SIMON (FR) | 2021-07-29 | — | — | US | disclosed |
| EP-3827241-A1 | DISSOCIATION OF BIOLOGICAL SAMPLES | Goldsborough, Andrew Simon (FR) | 2021-06-02 | — | — | EP | disclosed |
| EP-3788873-A1 | SAMPLE FIXATION AND STABILISATION | Goldsborough, Andrew Simon (FR) | 2021-03-10 | — | — | EP | disclosed |
| US-7759397-B2 | 6-amino(aza)indane compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBOTT GMBH & CO. KG (DE) | 2010-07-20 | — | — | US | disclosed |
| US-20090143383-A1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2009-06-04 | — | — | US | disclosed |
| US-20090048326-A1 | Azabicycloheptyl compounds suitable for treating disorders that respond to modulation of the dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-02-19 | — | — | US | disclosed |
| EP-2013179-A1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | Abbott GmbH & Co. KG (DE) | 2009-01-14 | — | — | EP | disclosed |
| US-20090012074-A1 | Arylsulfonylmethyl or arylsulfonamide substituted aromatic compounds suitable for treating disorders that respond to modulation of the Dopamine D3 receptor | ABBVIE DEUTSCHLAND GMBH & CO KG (DE) | 2009-01-08 | — | — | US | disclosed |
| US-20080318996-A1 | 6-Amino(Aza)Indane Compounds Suitable for Treating Disorders that Respond to Modulation of the Dopamine D3 Receptor | ABBOTT GMBH & CO.KG A CORPORATION | 2008-12-25 | — | — | US | disclosed |
| US-20080096934-A1 | Aminoethylaromatic Compounds Suitable For Treating Disorders That Respond To Modulation Of The Dopamine D3 Receptor | ABBOTT GMBH & CO. KG (DE) | 2008-04-24 | — | — | US | disclosed |
| WO-2007118859-A1 | ARYLOXYETHYLAMINE COMPOUNDS SUITABLE FOR TREATING DISORDERS THAT RESPOND TO MODULATION OF THE DOPAMINE D3 RECEPTOR | ABBOTT GMBH & CO. KG (DE) | 2007-10-25 | — | — | WO | disclosed |